Nyheter

Cyxone strengthens team ahead of continued development of T20K and Rabeximod

Malin Berthold holds a doctoral degree in neurochemistry from Stockholm University. During her career, Malin has accumulated extensive and diverse experience in the life science field. She started out as a researcher but since then has spent many years in various project leader and managerial roles in preclinical research and has been a senior scientific advisor in Global Marketing and Medical Affairs in global companies. Malin has also previously founded a life science consulting company and helped small and medium-sized pharmaceutical and medtech companies to strengthen their scientific positioning in the market.

Kjell G. Stenberg, CEO of Cyxone, commented: ”We see that Malin will bring great knowledge to the company thanks to her broad expertise in pharmacology, preclinical and clinical studies as well as her deep experience in leadership and project management. In addition, her solid work as a board member and scientific adviser in previous projects will be a great asset for Cyxone, which is currently in an incredibly exciting development and growth phase.”

Malin most recently comes from ImmunoDiagnostics at ThermoFischer Scientific, an internationally leading company in allergy and autoimmunity. She begins her role at Cyxone with immediate effect.

Contact
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
Email: kjell.g.stenberg@cyxone.com
Adelgatan 21
211 22 Malmö, Sweden

About Cyxone
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North is Mangold Fondkommission AB, +46 (0)8-503 015 50, ca@mangold.se.www.cyxone.com